Arielle Medford
Medical Oncologist · Massachusetts General Hospital
Credentials: · · · · ·
History
- 2022–2023
- 2016–2019
- 2012–2016
Research
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
Clinical Cancer Research · 2016 · 149 citations
Ki-67 is required for maintenance of cancer stem cells but not cell proliferation
Oncotarget · 2016 · 77 citations
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
Journal of Clinical Investigation · 2019 · 50 citations
26 papers
- LS
14 papers
- SW
14 papers · 1 as a fellow
- LE
12 papers
11 papers
- CM
10 papers
10 papers
10 papers
Clinical trials
- 2017–2026
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Massachusetts General Hospital
- 2026–2037